Previous 10 | Next 10 |
home / stock / sny / sny articles
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in a...
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA's (...
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies ar...
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson&n...
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development program of tusamitamab ravtansine. The decision is ba...
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combine...
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium announce that the European Medicines Agency’s (EMA) Committee for ...
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic...
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, ...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...
2024-06-09 09:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...